Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(VX702; VX 702)
VX-702 Chemical Structure
|Product name: VX-702|
|Cat. No.: HY-10401|
VX-702 is a highly selective inhibitor of p38α MAPK(IC50=4 -20 nM), 14-fold higher potency against the p38α versus p38β.
IC50 value: 4-20 nM 
Target: p38α MAPK
in vitro: Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies . VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner .
in vivo: The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally . VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score .
|M.Wt||404.32||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO ≥78mg/mL Water <1.2mg/mL Ethanol ≥2.8mg/mL
|1 mg||5 mg||10 mg|
|1 mM||2.4733 mL||12.3664 mL||24.7329 mL|
|5 mM||0.4947 mL||2.4733 mL||4.9466 mL|
|10 mM||0.2473 mL||1.2366 mL||2.4733 mL|
BMS-582949 hydrochloride is a novel highly selective p38(alpha) MAPK inhibitor, inhibits p38(alpha) with IC50 of 13 nM.
Doramapimod (BIRB 796) is a highly selective p38(alpha) MAPK inhibitor with Kd of 0.1 nM, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2, ZAP-70, EGFR, HER2, PKA, PKC, PKC(alpha)/(beta)/(gamma).
Losmapimod (GW856553X; SB856553; GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38(alpha) and p38(beta), respectively.
LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38(alpha)MAPK and p38(beta)MAPK were 7 nM and 3 nM, respectively).
p38 MAPK-IN-1 is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM, shows sustained levels, low clearance and good bioavailability.
PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor (IC50 = 89 nM).
SB 202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase with IC50 values of 50 nM and 100 nM for p38(alpha) and p38(beta) respectively; also showed slightly weaker activity for BRD4 (Kd=3.4 uM).
SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38(alpha)). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580.
SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM.